Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
2.
Immunol Rev ; 293(1): 38-56, 2020 01.
Article in English | MEDLINE | ID: mdl-31556468

ABSTRACT

Developing efficacious vaccines for human malaria caused by Plasmodium falciparum is a major global health priority, although this has proven to be immensely challenging over the decades. One major hindrance is the incomplete understanding of specific immune responses that confer protection against disease and/or infection. While antibodies to play a crucial role in malaria immunity, the functional mechanisms of these antibodies remain unclear as most research has primarily focused on the direct inhibitory or neutralizing activity of antibodies. Recently, there is a growing body of evidence that antibodies can also mediate effector functions through activating the complement system against multiple developmental stages of the parasite life cycle. These antibody-complement interactions can have detrimental consequences to parasite function and viability, and have been significantly associated with protection against clinical malaria in naturally acquired immunity, and emerging findings suggest these mechanisms could contribute to vaccine-induced immunity. In order to develop highly efficacious vaccines, strategies are needed that prioritize the induction of antibodies with enhanced functional activity, including the ability to activate complement. Here we review the role of complement in acquired immunity to malaria, and provide insights into how this knowledge could be used to harness complement in malaria vaccine development.


Subject(s)
Complement System Proteins/immunology , Host-Parasite Interactions/immunology , Malaria Vaccines/immunology , Malaria, Falciparum/immunology , Malaria, Falciparum/prevention & control , Plasmodium falciparum/immunology , Animals , Antibodies, Protozoan/immunology , Complement Activation/immunology , Disease Models, Animal , Erythrocytes/immunology , Erythrocytes/metabolism , Erythrocytes/parasitology , Humans , Immunity, Innate , Immunization, Passive , Malaria Vaccines/administration & dosage , Plasmodium falciparum/growth & development
3.
J Immunol ; 198(12): 4728-4737, 2017 06 15.
Article in English | MEDLINE | ID: mdl-28484054

ABSTRACT

The complement system is a front-line defense system that opsonizes and lyses invading pathogens. To survive, microbes exposed to serum must evade the complement response. To achieve this, many pathogens recruit soluble human complement regulators to their surfaces and hijack their regulatory function for protection from complement activation. C1 esterase inhibitor (C1-INH) is a soluble regulator of complement activation that negatively regulates the classical and lectin pathways of complement to protect human tissue from aberrant activation. In this article, we show that Plasmodium falciparum merozoites, the invasive form of blood stage malaria parasites, actively recruit C1-INH to their surfaces when exposed to human serum. We identified PfMSP3.1, a member of the merozoite surface protein 3 family of merozoite surface proteins, as the direct interaction partner. When bound to the merozoite surface, C1-INH retains its ability to complex with and inhibit C1s, MASP1, and MASP2, the activating proteases of the complement cascade. P. falciparum merozoites that lack PfMSP3.1 showed a marked reduction in C1-INH recruitment and increased C3b deposition on their surfaces. However, these ΔPfMSP3.1 merozoites exhibit enhanced invasion of RBCs in the presence of active complement. This study characterizes an immune-evasion strategy used by malaria parasites and highlights the complex relationship between merozoites and the complement system.


Subject(s)
Antigens, Protozoan/metabolism , Complement Activation , Complement C1 Inhibitor Protein/metabolism , Immune Evasion , Membrane Proteins/metabolism , Merozoites/immunology , Plasmodium falciparum/immunology , Antigens, Protozoan/immunology , Complement C1 Inhibitor Protein/genetics , Complement C1s/antagonists & inhibitors , Complement C1s/immunology , Complement C1s/metabolism , Erythrocytes/parasitology , Humans , Mannose-Binding Protein-Associated Serine Proteases/antagonists & inhibitors , Mannose-Binding Protein-Associated Serine Proteases/immunology , Mannose-Binding Protein-Associated Serine Proteases/metabolism , Membrane Proteins/immunology , Merozoites/chemistry , Plasmodium falciparum/growth & development , Plasmodium falciparum/metabolism
4.
J Immunol ; 196(3): 1239-48, 2016 Feb 01.
Article in English | MEDLINE | ID: mdl-26700768

ABSTRACT

The human complement system is the frontline defense mechanism against invading pathogens. The coexistence of humans and microbes throughout evolution has produced ingenious molecular mechanisms by which microorganisms escape complement attack. A common evasion strategy used by diverse pathogens is the hijacking of soluble human complement regulators to their surfaces to afford protection from complement activation. One such host regulator is factor H (FH), which acts as a negative regulator of complement to protect host tissues from aberrant complement activation. In this report, we show that Plasmodium falciparum merozoites, the invasive form of the malaria parasites, actively recruit FH and its alternative spliced form FH-like protein 1 when exposed to human serum. We have mapped the binding site in FH that recognizes merozoites and identified Pf92, a member of the six-cysteine family of Plasmodium surface proteins, as its direct interaction partner. When bound to merozoites, FH retains cofactor activity, a key function that allows it to downregulate the alternative pathway of complement. In P. falciparum parasites that lack Pf92, we observed changes in the pattern of C3b cleavage that are consistent with decreased regulation of complement activation. These results also show that recruitment of FH affords P. falciparum merozoites protection from complement-mediated lysis. Our study provides new insights on mechanisms of immune evasion of malaria parasites and highlights the important function of surface coat proteins in the interplay between complement regulation and successful infection of the host.


Subject(s)
Complement Activation/immunology , Complement Factor H/immunology , Immune Evasion/immunology , Malaria, Falciparum/immunology , Blotting, Western , Flow Cytometry , Fluorescent Antibody Technique , Humans , Immunoprecipitation , Merozoites/immunology
5.
J Biol Chem ; 290(42): 25307-21, 2015 Oct 16.
Article in English | MEDLINE | ID: mdl-26324715

ABSTRACT

Plasmodium falciparum parasites must invade red blood cells to survive within humans. Entry into red blood cells is governed by interactions between parasite adhesins and red blood cell receptors. Previously we identified that P. falciparum reticulocyte binding protein-like homologue 4 (PfRh4) binds to complement receptor 1 (CR1) to mediate entry of malaria parasites into human red blood cells. In this report we characterize a collection of anti-PfRh4 monoclonal antibodies and CR1 protein fragments that modulate the interaction between PfRh4 and CR1. We identify an anti-PfRh4 monoclonal that blocks PfRh4-CR1 interaction in vitro, inhibits PfRh4 binding to red blood cells, and as a result abolishes the PfRh4-CR1 invasion pathway in P. falciparum. Epitope mapping of anti-PfRh4 monoclonal antibodies identified distinct functional regions within PfRh4 involved in modulating its interaction with CR1. Furthermore, we designed a set of protein fragments based on extensive mutagenesis analyses of the PfRh4 binding site on CR1 and determined their interaction affinities using surface plasmon resonance. These CR1 protein fragments bind tightly to PfRh4 and also function as soluble inhibitors to block PfRh4 binding to red blood cells and to inhibit the PfRh4-CR1 invasion pathway. Our findings can aid future efforts in designing specific single epitope antibodies to block P. falciparum invasion via complement receptor 1.


Subject(s)
Antibodies, Monoclonal/immunology , Erythrocytes/metabolism , Membrane Proteins/metabolism , Protozoan Proteins/metabolism , Receptors, Complement/metabolism , Animals , Membrane Proteins/antagonists & inhibitors , Membrane Proteins/immunology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Protozoan Proteins/antagonists & inhibitors , Protozoan Proteins/immunology
7.
Mol Immunol ; 67(1): 71-84, 2015 Sep.
Article in English | MEDLINE | ID: mdl-25816986

ABSTRACT

Malaria remains one of the world's deadliest diseases. Plasmodium falciparum is responsible for the most severe and lethal form of human malaria. P. falciparum's life cycle involves two obligate hosts: human and mosquito. From initial entry into these hosts, malaria parasites face the onslaught of the first line of host defence, the complement system. In this review, we discuss the complex interaction between complement and malaria infection in terms of hosts immune responses, parasite survival and pathogenesis of severe forms of malaria. We will focus on the role of complement receptor 1 and its associated polymorphisms in malaria immune complex clearance, as a mediator of parasite rosetting and as an entry receptor for P. falciparum invasion. Complement evasion strategies of P. falciparum parasites will also be highlighted. The sexual forms of the malaria parasites recruit the soluble human complement regulator Factor H to evade complement-mediated killing within the mosquito host. A novel evasion strategy is the deployment of parasite organelles to divert complement attack from infective blood stage parasites. Finally we outline the future challenge to understand the implications of these exploitation mechanisms in the interplay between successful infection of the host and pathogenesis observed in severe malaria.


Subject(s)
Complement C3b Inactivator Proteins/immunology , Life Cycle Stages/immunology , Malaria, Falciparum/immunology , Plasmodium falciparum/immunology , Receptors, Complement/immunology , Antigen-Antibody Complex/chemistry , Antigen-Antibody Complex/genetics , Complement Activation , Complement C3b Inactivator Proteins/genetics , Complement Factor H/genetics , Complement Factor H/immunology , Gene Expression , Humans , Immune Evasion , Life Cycle Stages/genetics , Malaria, Falciparum/genetics , Malaria, Falciparum/parasitology , Malaria, Falciparum/pathology , Plasmodium falciparum/genetics , Plasmodium falciparum/growth & development , Polymorphism, Genetic , Receptors, Complement/genetics
8.
Antioxid Redox Signal ; 17(4): 634-56, 2012 Aug 15.
Article in English | MEDLINE | ID: mdl-22320355

ABSTRACT

SIGNIFICANCE: Heme is an essential prosthetic group for most life on Earth. It functions in numerous cellular redox reactions, including in antioxidant defenses and at several stages of the electron transport chain in prokaryotes and eukaryotic mitochondria. Heme also functions as a sensor and transport molecule for gases such as oxygen. Heme is a complex organic molecule and can only be synthesized through a multienzyme pathway from simpler precursors. Most free-living organisms synthesize their own heme by a broadly conserved metabolic pathway. Parasites are adept at scavenging molecules from their hosts, and heme is no exception. RECENT ADVANCES: In this review we examine recent advances in understanding heme usage and acquisition in Apicomplexa, a group of parasites that include the causative agents of malaria, toxoplasmosis, and several major parasites of livestock. CRITICAL ISSUES: Heme is critical to the survival of Apicomplexa, although the functions of heme in these organisms remain poorly understood. Some Apicomplexa likely scavenge heme from their host organisms, while others retain the ability to synthesize heme. Surprisingly, some Apicomplexa may be able to both synthesize and scavenge heme. Several Apicomplexa live in intracellular environments that contain high levels of heme. Since heme is toxic at high concentrations, parasites must carefully regulate intracellular heme levels and develop mechanisms to detoxify excess heme. Indeed, drugs interfering with heme detoxification serve as major antimalarials. FUTURE DIRECTIONS: Understanding heme requirements and regulation in apicomplexan parasites promises to reveal multiple targets for much-needed therapeutic intervention against these parasites.


Subject(s)
Apicomplexa/metabolism , Heme/metabolism , Animals , Subcellular Fractions/metabolism
9.
Biomaterials ; 33(3): 979-88, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22048009

ABSTRACT

Retinal neuroinflammation, mediated by activated microglia, plays a key role in the pathogenesis of photoreceptor and retinal pigment epithelial cell loss in age-related macular degeneration and retinitis pigmentosa. Targeted drug therapy for attenuation of neuroinflammation in the retina was explored using hydroxyl-terminated polyamidoamine (PAMAM) dendrimer-drug conjugate nanodevices. We show that, upon intravitreal administration, PAMAM dendrimers selectively localize within activated outer retinal microglia in two rat models of retinal degeneration, but not in the retina of healthy controls. This pathology-dependent biodistribution was exploited for drug delivery, by covalently conjugating fluocinolone acetonide to the dendrimer. The conjugate released the drug in a sustained manner over 90 days. In vivo efficacy was assessed using the Royal College of Surgeons (RCS) rat retinal degeneration model over a four-week period when peak retinal degeneration occurs. One intravitreal injection of 1 µg of FA conjugated to 7 µg of the dendrimer was able to arrest retinal degeneration, preserve photoreceptor outer nuclear cell counts, and attenuate activated microglia, for an entire month. These studies suggest that PAMAM dendrimers (with no targeting ligands) have an intrinsic ability to selectively localize in activated microglia, and can deliver drugs inside these cells for a sustained period for the treatment of retinal neuroinflammation.


Subject(s)
Anti-Inflammatory Agents/chemistry , Anti-Inflammatory Agents/therapeutic use , Dendrimers/chemistry , Fluocinolone Acetonide/chemistry , Fluocinolone Acetonide/therapeutic use , Retinal Degeneration/drug therapy , Retinal Degeneration/immunology , Animals , Electroretinography , Inflammation/drug therapy , Intravitreal Injections , Neuroimmunomodulation/drug effects , Rats
10.
Curr Eye Res ; 36(2): 168-77, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21158590

ABSTRACT

PURPOSE: To study the relationship of oxygen level and glucose concentration on the secretion of vascular endothelial growth factor (VEGF) mRNA and protein in several types of cultured retinal cells. MATERIALS AND METHODS: Several types of human and bovine retinal cells were cultured in medium without glucose, or containing 5 mM or 25 mM D-glucose or 5 mM D-glucose and 20 mM D-galactose. Cells were cultured in 20% O(2) ("normoxia") or in 1% O(2) ("hypoxia"). After being cultured for 8-96 hr, we measured VEGF protein in the medium and VEGF mRNA in the cell layer, as well as the concentrations of glucose, lactate, and pyruvate in the medium. RESULTS: Hypoxia increased VEGF mRNA and protein in these cells. In normoxia, culture in high glucose medium had no significant effect on basal VEGF production in normal glucose. However, culture in hypoxia and high glucose significantly blunted hypoxic VEGF up-regulation. Culture in normoxia, with no glucose in the medium, significantly increased VEGF. Culture in high galactose medium did not significantly affect VEGF production. Despite considerable lactate production, especially in the presence of 25 mM glucose, addition of strong buffers to the medium had little effect on VEGF production. CONCLUSIONS: Cultured retinal cells up-regulate their VEGF production when their energy supply, including glucose and/or O(2), is inadequate. Supplying glucose to the cells in the presence of low O(2) reduces their VEGF production. We suggest that "early worsening" of retinopathy results when diabetic patients with minimal to moderate retinopathy, whose retinal circulation and, hence, retinal oxygen supply is compromised, are placed on a "tight" glucose control regimen and their major remaining retinal energy source is reduced, with VEGF up-regulation as a compensatory mechanism.


Subject(s)
Endothelium, Vascular/drug effects , Glucose/pharmacology , Hypoxia/metabolism , Retinal Neurons/drug effects , Vascular Endothelial Growth Factor B/metabolism , Animals , Cattle , Cells, Cultured , Endothelium, Vascular/metabolism , Humans , Lactic Acid/metabolism , Pyruvic Acid/metabolism , RNA, Messenger/metabolism , Retinal Neurons/metabolism , Up-Regulation , Vascular Endothelial Growth Factor B/genetics
11.
Invest Ophthalmol Vis Sci ; 51(8): 4243-52, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20220055

ABSTRACT

PURPOSE: To study the neuroprotective properties of low-dose, sustained-release intravitreous fluocinolone acetonide (FA) in transgenic S334ter-4 rats. METHODS: S334ter-4 rats aged 4 weeks were divided into four groups: 0.5 microg/d FA-loaded intravitreous drug delivery implant (IDDI); 0.2 microg/d FA-loaded IDDI; inactive IDDI; and unoperated controls. Electroretinography (ERG) was performed before surgery and every 2 weeks after surgery for 8 weeks. When the rats were 12 weeks of age, outer nuclear layer (ONL) and inner nuclear layer (INL) thicknesses were measured. Microglial cell counts were obtained from retinal wholemounts labeled for Iba-1. RESULTS: At the end of the study, unoperated and inactive IDDI-implanted rats demonstrated 50% to 60% reductions in ERG amplitudes compared with those recorded at 4 weeks (P < 0.001 for both groups). FA 0.2-microg/d animals demonstrated 15% amplitude attenuation, while FA 0.5-microg/d animals showed 30% reduction. ONL thickness in FA 0.2-microg/d-treated eyes was 25.8% +/- 2.3% higher than in control group eyes (P < 0.001) and 30.0% +/- 2.1% higher than in inactive IDDI-implanted eyes (P < 0.001). In FA 0.5-microg/d-treated eyes, ONL thickness was 22.4% +/- 2.8% higher than in control group eyes (P < 0.001) and 22.3% +/- 3.7% higher than in inactive IDDI-implanted eyes (P < 0.01). No statistically significant difference was observed between the two control groups. No statistically significant difference between the two FA-treated groups was found. FA-treated groups demonstrated significantly fewer activated microglial cells than control groups. CONCLUSIONS: Chronic intravitreous infusion of FA preserves ONL cell morphology and ERG a- and b-wave amplitudes and reduces retinal neuroinflammation in S334ter rats. Based on these findings, the synthetic corticosteroid FA may promise a therapeutic role in patients with retinal degeneration.


Subject(s)
Disease Models, Animal , Drug Delivery Systems , Fluocinolone Acetonide/administration & dosage , Glucocorticoids/administration & dosage , Retina/drug effects , Retinal Degeneration/prevention & control , Animals , Animals, Genetically Modified , Cell Count , Electroretinography/drug effects , Microglia/drug effects , Microglia/pathology , Rats , Retina/physiology , Retinal Degeneration/physiopathology , Vitreous Body
12.
Invest Ophthalmol Vis Sci ; 50(10): 4847-57, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19407016

ABSTRACT

PURPOSE: To study the neuroprotective effects of intravitreal fluocinolone acetonide (FA) in Royal College of Surgeons (RCS) rats. METHODS: Five-week-old RCS rats were divided into four groups: 0.5 microg/d FA-loaded intravitreal drug-delivery implant (IDDI); 0.2 microg/d FA-loaded IDDI; inactive IDDI; and nonsurgical control. Electroretinography (ERG) and intraocular pressure (IOP) measurements were performed before surgery and weekly thereafter. Thicknesses of the retinal outer (ONL) and inner (INL) nuclear layers were evaluated at 9 weeks of age. ED-1-labeled activated microglia were counted. Total microglial cell counts were made by using Iba-1 antibody labeling. RESULTS: At 9 weeks, control groups demonstrated an 80% reduction in ERG amplitudes (P < 0.001 for both groups). FA-treated groups demonstrated no statistically significant attenuation of ERG amplitudes at the end of the study, compared with the initial ERGs. Intraocular pressure (IOP) remained normal in all groups. ONL thickness in FA 0.2 microg/d-treated eyes was 2.1 +/- 0.5 times greater than in nonsurgical eyes (P < 0.001) and 3.4 +/- 0.7 times greater than in inactive IDDI-treated eyes (P < 0.0001). In FA 0.5 microg/d-treated eyes, ONL thickness was 1.5 +/- 0.1 times higher than in nonsurgical controls (P < 0.05) and 2.4 +/- 0.4 times higher than in inactive IDDI-treated eyes (P < 0.01). INL thickness was not different among groups. FA-treated eyes demonstrated significantly fewer activated microglia (P < 0.001) and overall number of microglia in the photoreceptor and outer debris zone layers (P < 0.001), compared with control groups. CONCLUSIONS: Chronic intravitreal infusion of FA is neuroprotective in RCS rats, preserves ONL morphology and ERG amplitudes and reduces retinal neuroinflammation. These findings may have a therapeutic role in human photoreceptor cell degenerations.


Subject(s)
Fluocinolone Acetonide/administration & dosage , Glucocorticoids/administration & dosage , Neuroprotective Agents/administration & dosage , Photoreceptor Cells, Vertebrate/drug effects , Retinitis Pigmentosa/drug therapy , Animals , Cell Count , Drug Delivery Systems , Drug Implants , Electroretinography/drug effects , Female , Intraocular Pressure/drug effects , Male , Microglia/pathology , Photoreceptor Cells, Vertebrate/physiology , Rats , Rats, Mutant Strains , Retinitis Pigmentosa/physiopathology , Vitreous Body
13.
Exp Diabetes Res ; 2007: 21976, 2007.
Article in English | MEDLINE | ID: mdl-17641740

ABSTRACT

AIM: Diabetic retinopathy resists reversal after good glycemic control (GC) is reinitiated, and preexisting damage at the time of intervention is considered as the major factor in determining the outcome of the GC. This study is to investigate the role of peroxynitrite accumulation in the retinal capillaries in the failure of retinopathy to reverse after reestablishment of GC, and to determine the effect of this reversal on the activity of the enzyme responsible for scavenging mitochondrial superoxide, MnSOD. METHODS: In streptozotocin-diabetic rats, 6 months of poor glycemic control (PC, glycated hemoglobin, GHb > 12.0%) was followed by 6 additional months of GC (GHb about 6%). The trypsin-digested retinal microvessels were prepared for immunostaining of nitrotyrosine (a measure of peroxynitrite) and for counting the number of acellular capillaries (a measure of histopathology). The retina from the other eye was used to quantify nitrotyrosine concentration, MnSOD activity and the total antioxidant capacity. RESULTS: Reversal of hyperglycemia after 6 months of PC had no significant effect on nitrotyrosine concentration in the retina, on the nitrotyrosine-positive retinal capillary cells and on the number of acellular capillaries; the values were similar in PC-GC and PC groups. In the same rats retinal MnSOD activity remained inhibited and the total antioxidant capacity was subnormal 6 months after cessation of PC. CONCLUSIONS: Peroxynitrite accumulation in the retinal microvasculature, the site of histopathology, fails to normalize after reversal of hyperglycemia, and superoxide remains inadequately scavenged. This failure of reversal of peroxynitrite accumulation could be, in part, responsible for the resistance of diabetic retinopathy to reverse after termination of PC.


Subject(s)
Diabetes Mellitus, Experimental/metabolism , Peroxynitrous Acid/metabolism , Retinal Vessels/metabolism , Animals , Antioxidants/metabolism , Blood Glucose/metabolism , Capillaries/metabolism , Capillaries/pathology , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/pathology , Glycated Hemoglobin/metabolism , Immunologic Techniques , Insulin/pharmacology , Male , Osmolar Concentration , Rats , Rats, Inbred Lew , Retina/metabolism , Retina/pathology , Retinal Vessels/pathology , Staining and Labeling , Superoxide Dismutase/metabolism , Tyrosine/analogs & derivatives , Tyrosine/metabolism
14.
J Homosex ; 48(2): 61-81, 2004.
Article in English | MEDLINE | ID: mdl-15774355

ABSTRACT

This article re-assesses the theories of death, narcissism and identification from a selection of essays by Sigmund Freud and Jacques Lacan in order to demonstrate that gender is generated out of masochism and the 'death drive' (Todestrieb). In closely reading and amending key sections of Judith Butler's queer theories, the author argues against her Foucaltian claim that the queer subject is constituted in the face of a sadistic Law, which s/he is forced to eroticise and internalise, and therefore conflate with her/his own masochism. It is argued that the subject's masochism is a queer attempt not to be; to bridge the constitutional split enforced by the Lacanian idea of the assumption of subjectivity through misidentification, and to become a living mortuary for the (dead) identifications that found the subject on his/her illusory ground through the (contingent) foreclosure of the Other.


Subject(s)
Death , Gender Identity , Homosexuality/psychology , Masochism/psychology , Animals , Attitude to Death , Female , Humans , Male , Narcissism , Psychological Theory , Thanatology
15.
Gynecol Oncol ; 91(2): 421-2, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14599876

ABSTRACT

OBJECTIVES: Radiation recall dermatitis secondary to gemcitabine use has been reported in isolated cases of patients treated for breast and lung cancers. There have been no reports of radiation recall dermatitis from gemcitabine after whole pelvic radiation therapy employed as a treatment of a gynecologic cancer. CASE: A 67-year-old woman was treated with whole pelvic radiation for palliation of lower extremity swelling and pain due to recurrent ovarian adenocarcinoma. Three months later, the patient was treated with gemcitabine for three courses. Therapy was discontinued secondary to severe cellulitis and edema of the skin of the anterior abdominal wall in the field of her prior radiation therapy. CONCLUSIONS: Radiation recall dermatitis secondary to gemcitabine should be considered in any patient with pelvic or lower abdominal skin abnormalities after pelvic radiation and subsequent gemcitabine therapy.


Subject(s)
Adenocarcinoma/radiotherapy , Antimetabolites, Antineoplastic/adverse effects , Deoxycytidine/analogs & derivatives , Deoxycytidine/adverse effects , Ovarian Neoplasms/radiotherapy , Radiation-Sensitizing Agents/adverse effects , Radiodermatitis/etiology , Aged , Cystadenocarcinoma, Papillary/radiotherapy , Cystadenocarcinoma, Serous/radiotherapy , Female , Humans , Gemcitabine
16.
J Am Acad Dermatol ; 49(3): 541-3, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12963928

ABSTRACT

Malignant acanthosis nigricans is recognized as a cutaneous sign of internal malignancy, usually an adenocarcinoma. Although cases of malignant acanthosis nigricans have been associated with cervical, ovarian, and endometrial neoplasms, we describe a case with a rarely if ever reported association, endometrioid adenocarcinoma of the parametrium.


Subject(s)
Acanthosis Nigricans/complications , Adenocarcinoma/etiology , Endometrial Neoplasms/etiology , Acanthosis Nigricans/pathology , Adenocarcinoma/pathology , Adenocarcinoma/therapy , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biopsy, Needle , Carboplatin/administration & dosage , Chemotherapy, Adjuvant , Endometrial Neoplasms/pathology , Endometrial Neoplasms/therapy , Female , Follow-Up Studies , Humans , Hysterectomy/methods , Immunohistochemistry , Paclitaxel/administration & dosage , Risk Assessment , Treatment Outcome
17.
Microbiology (Reading) ; 148(Pt 12): 3921-3931, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12480896

ABSTRACT

The interactions of group B streptococci (GBS) with HeLa cells (an epithelial cell line) and MRC-5 cells (a fibroblastic cell line) were explored. A host-cell invasion assay using GBS strains from all serotypes revealed that GBS invaded HeLa cells to a greater extent than MRC-5 cells. One strain, a serotype V (NCS13), was highly invasive against HeLa cells. All strains were poorly invasive against MRC-5 cells. Further characterization of the binding of NCS13 to HeLa and MRC-5 cell surfaces showed that the lack of recoverable c.f.u. from MRC-5 cells was due to a lack of binding of NCS13 to the MRC-5 cell surface in comparison to HeLa cells. Although fibronectin had been reported to bind to GBS, fibronectin assays showed 2.7-fold more fibronectin on the MRC-5 cell surface in comparison to HeLa cells, suggesting that other extracellular matrix proteins besides fibronectin may be involved in GBS binding. Scanning electron microscopy of NCS13 and HeLa cells over a 6 h time period showed increased numbers of NCS13 on the HeLa cell surface over time until cell death at 6 h. Direct contact of the HeLa cell surface by NCS13 was found to be necessary for cell death to occur. Further scanning electron microscopy studies found that, once GBS are bound to the HeLa cell surface, HeLa cell microvilli entwine the bacteria, which then enter the HeLa cell in a polar fashion. Cytoskeletal actin is involved, as this process is disrupted by cytochalasin D, and recruitment of actin is visible at the site of adherent chains of GBS. Also, the host-cell signalling enzyme, PI 3-kinase, is involved in the GBS internalization process, since the PI 3-kinase inhibitor, wortmannin, inhibited NCS13 invasion of HeLa cells in a dose-dependent manner.


Subject(s)
Bacterial Adhesion , Fibroblasts/microbiology , HeLa Cells/microbiology , Streptococcus agalactiae/metabolism , Streptococcus agalactiae/pathogenicity , Actins/metabolism , Adult , Aged , Aged, 80 and over , Cell Line , Cytochalasin D , Fibronectins/metabolism , Humans , Infant , Infant, Newborn , Microscopy, Electron, Scanning , Middle Aged , Phosphatidylinositol 3-Kinases/metabolism , Streptococcus agalactiae/physiology
18.
Gynecol Oncol ; 86(3): 361-4, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12217762

ABSTRACT

OBJECTIVE: The objective of this study was to study further the management of cervical adenocarcinoma in situ (AIS) with particular regard to the results of conservative management without hysterectomy and the use of large loop excision of the transformation zone (LLETZ). METHODS: Based upon the files of the Pathology Department at the Cleveland Clinic Foundation, recently encountered AIS patients were combined with patients from a previous study that ended in 1994. Charts and clinical materials were retrospectively reviewed and abstracted. RESULTS: Fifty-two patients were identified for a combined study group of 98 patients. The mean age was 37 years. Fifty-two percent were identified due to abnormal squamous elements on a Pap smear and 43% due to abnormal glandular cells. In patients treated with hysterectomy, 67% were found to have residual disease following conization with positive margins including 3 patients with invasive cancer. Among all patients, LLETZ was associated with a positive margin rate of 57.1% vs 27.3% with cold knife conization (CKC) (chi(2), P = 0.008). Among patients treated conservatively with conization, the rates of positive margins were 40.0 and 20.0%, respectively, for LLETZ and CKC (chi(2), P = 0.11); 9.5% of conservatively managed patients with negative initial conization margins eventually had recurrent AIS. CONCLUSION: Cold knife conization is the preferred method of management for cervical AIS patients selecting conservative treatment. Despite initial conization margins being uninvolved, such patients have an approximate risk of 10% for recurrent AIS.


Subject(s)
Adenocarcinoma/surgery , Carcinoma in Situ/surgery , Uterine Cervical Neoplasms/surgery , Adult , Conization/methods , Electrosurgery/methods , Female , Humans , Uterine Cervical Neoplasms/pathology
19.
Gynecol Oncol ; 86(1): 95-8, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12079307

ABSTRACT

BACKGROUND: A strong rationale can be proposed to support the delivery of paclitaxel by both the intravenous and the intraperitoneal routes in the management of ovarian cancer. This includes efforts to increase the concentration and duration of exposure of this cycle-specific agent within the body compartment (regional therapy) and a desire to optimize delivery of drug to tumor by capillary flow (systemic therapy). CASE REPORTS: Two patients cared for in the Gynecologic Cancer Program of the Cleveland Clinic Foundation provided an opportunity to explore, in a preliminary manner, the feasibility and toxicity of this unique approach. Both patients demonstrated reasonable tolerance of the dual-route management strategy. CONCLUSION: In a carefully selected patient population, the administration of paclitaxel both systemically and regionally is a rational management strategy. Randomized controlled clinical trials will be required to determine if this approach is superior to standard intravenous drug delivery.


Subject(s)
Antineoplastic Agents, Phytogenic/administration & dosage , Ovarian Neoplasms/drug therapy , Paclitaxel/administration & dosage , Female , Humans , Infusions, Intravenous , Infusions, Parenteral , Middle Aged
20.
J Reprod Med ; 47(1): 9-13, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11838315

ABSTRACT

OBJECTIVE: To analyze our experience with 400 Thin-Prep (TP) split samples (Cytyc Corp., Boxborough, Massachusetts) as an initial assessment of this new technology's effect in our laboratory. STUDY DESIGN: Three gynecologic oncologists and two general gynecologists obtained the 400 split samples using a broom sampling device. Following conventional smear (CS) preparation, they rinsed the broom in Preservcyt solution (Cytyc) for subsequent TP processing. The paired samples were separated, independently analyzed and classified by the Bethesda System. All available follow-up surgical pathology material was reviewed and compared to the cytologic diagnoses. RESULTS: TP had significantly more abnormal results (22% vs. 16%, P = .007), including more atypical squamous cells of undetermined significance (ASCUS) (9.5% vs. 6.3% P = .07) and low grade squamous intraepithelial lesion (LSIL) (7.8% vs. 5.3%, P = .03). Both methods had 3.3% high grade squamous intraepithelial lesion (HSIL). For TP, ASCUS/squamous intraepithelial lesion (SIL) = 0.86 and for CS, ASCUS/SIL = 0.74. Ten TP SILs had a paired negative CS, including LSIL (nine cases) and HSIL (one case). Consensus review of these 10 TP slides confirmed the HSIL and four LSILs. No CS SILs had a paired negative TP. Only 36 (9%) cases had surgical pathology follow-up. The surgical specimens included 17 cervical intraepithelial neoplasia (CIN) 2 or above. The TP method had no false negatives, while the CS method had 3 false negatives among the 17 confirmed cases of CIN 2 or above. CONCLUSION: TP appears to be superior to CS for detecting SILs.


Subject(s)
Carcinoma, Squamous Cell/pathology , Papanicolaou Test , Uterine Cervical Dysplasia/pathology , Uterine Cervical Neoplasms/pathology , Vaginal Smears/methods , Culture Techniques , Diagnosis, Differential , Female , Humans , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...